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This mini-review focuses on noninvasive brain stimulation techniques as an augmentation
method for the treatment of persistent auditory verbal hallucinations (AVH) in patients with
schizophrenia. Paradigmatically, we place emphasis on transcranial magnetic stimulation
(TMS). We specifically discuss rationales of stimulation and consider methodological
questions together with issues of phenotypic diversity in individuals with drug-refractory
and persistent AVH. Eventually, we provide a brief outlook for future investigations and
treatment directions. Taken together, current evidence suggests TMS as a promising
method in the treatment of AVH. Low-frequency stimulation of the superior temporal
cortex (STC) may reduce symptom severity and frequency. Yet clinical effects are
of relatively short duration and effect sizes appear to decrease over time along
with publication of larger trials. Apart from considering other innovative stimulation
techniques, such as transcranial Direct Current Stimulation (tDCS), and optimizing
stimulation protocols, treatment of AVH using noninvasive brain stimulation will essentially
rely on accurate identification of potential responders and non-responders for these
treatment modalities. In this regard, future studies will need to consider distinct
phenotypic presentations of AVH in patients with schizophrenia, together with the
putative functional neurocircuitry underlying these phenotypes.
Keywords: transcranial magnetic stimulation, auditory verbal hallucinations, phenotypes, schizophrenia, brain
stimulation, brain function
Introduction
Auditory verbal hallucinations (AVH) are defined as auditive perceptions involving a verbal
aspect in the absence of a provoking external stimulus (Aleman and de Haan, 1998). They
represent a core symptom of schizophrenia and related spectrum disorders, but they also
frequently occur in other psychiatric entities and in the non-psychiatric general population.
In schizophrenia the term AVH comprises a multi-dimensional and heterogeneous group of
symptoms that can be differentiated by certain phenomenological aspects such as subjective
loudness, acoustic clarity, location and subjective reality. About 60–80% of patients affected
by schizophrenia experience AVH (Aleman and de Haan, 1998; Hugdahl et al., 2008), such
as conversing, commenting or imperative spoken speech in distinct voices. These symptoms,
especially when the verbal content is experienced as negative, intrusive or persecutory,
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often induce high levels of distress and lead to significant
psychosocial impairment. AVH are a highly relevant feature
of schizophrenia that have attracted extensive clinical,
phenomenological and neurobiological interest, yet treating
these symptoms, especially in persons suffering from persistent
AVH which do either not or not sufficiently respond to
psychopharmacotherapy, is still a major clinical challenge. In
approximately 25% of patients with schizophrenia, AVH are
refractory to psychotropic drug treatment and can chronically
persist (Shergill et al., 1998). Currently, there are no randomized
controlled trials available which specifically investigated effects
of psychopharmacotherapy (either monotherapy or combined
drug regimes) on AVH severity reduction or full symptom
remission. In a recent review (Sommer et al., 2012), data from
the European First-Episode Schizophrenia Trial (EUFEST)
was used to assess effects of five antipsychotic agents on AVH
severity. Superiority of one treatment option against another was
not confirmed for AVH severity (Sommer et al., 2012). Clinically,
clozapine is still the drug of choice for patients with AVH who
are resistant to two other antipsychotic agents. At present, no
clinical trial has been published that specifically compares the
efficacy of clozapine in comparison to other antipsychotic agents
in the treatment of drug-resistant AVH.
Transcranial Magnetic Stimulation
Given the need for effective treatment modalities, it is
not surprising to see that over the past decade brain
stimulation techniques have been increasingly used to ameliorate
symptom burden in patients with schizophrenia suffering from
persistent and mostly pharmacorefractory AVH. Among these
approaches, a possible augmentation strategy for the treatment
of psychiatric disorders (in particular catatonia and severe
depression) is elctroconvulsive therapy (ECT). For patients
with schizophrenia a meta-analysis of 10 double-blind RCT
showed a significant effect for ECT (Tharyan and Adams, 2005),
although none of the studies provided any specific details on
AVH improvement (Sommer et al., 2012). In a recent review
Nieuwdorp and colleagues summarized different stimulation
methods including transcranial magnetic stimulation (TMS),
ECT and transcranial Direct Current Stimulation (tDCS)
in patients with medication-resistant psychosis (Nieuwdorp
et al., 2015). The authors concluded that currently there
is only weak evidence for stimulation techniques to relieve
pharmacorefractory psychosis. Specifically considering AVH,
further studies are needed to draw any strong conclusions
about ECT as a treatment option for patients presenting with
persistent AVH.
In the last decade, TMS has evolved into a therapeutic
modality for several psychiatric and neurological symptoms. In
particular, TMS is widely used to treat patients with major
depression, obsessive-compulsive disorder (OCD) and specific
symptoms of schizophrenia (AVH and negative symptoms)
(Slotema et al., 2010). Its application as an adjunctive therapy is
currently proposed by European specialists with evidence level C
(Lefaucheur et al., 2014) taking into account that it is generally
regarded as safe. We consider the application of TMS for treating
individuals presenting with persistent AVH as paradigmatic. The
use of TMS impressively illustrates a translational approach from
basic neuroscience/neuroimaging to clinical treatment. However,
it also illustrates fundamental methodological, neurobiological
and phenomenological questions and challenges, which we will
refer to in the following paragraphs.
TMS: Putative Mechanisms of Action
TMS is a technique which allows a non-invasive stimulation
of cortical neurons through the scalp. Originally, TMS was
implemented as a neurophysiological tool for the study of the
human motor system (Barker et al., 1985). Put simply, TMS
uses a strong pulse of electrical current in a coil which is
placed over the brain generating rapidly pulsating magnetic
fields, which pass through the scalp, skull, and meninges,
into the brain (Wassermann and Zimmermann, 2012). Thus,
changing magnetic fields produce electrical impulses that
stimulate superficial cortical neurons 2–3 cm below the device
(Wassermann and Zimmermann, 2012). Modern devices can
generate a rapid succession of pulses, called repetitive TMS
(rTMS) by producing a relatively powerful magnetic field
(about 1.5–3T), but only lasting very shortly (ms) (George
and Aston-Jones, 2010). Frequencies of 1 Hz or lower are
considered to be inhibitory, while frequencies of 5 Hz and
higher are considered to be excitatory (Aleman, 2013). The
specific topology of the induced electrical field in the brain
is a source of uncertainty, because it is influenced by the
complex shape and diverse conductivity of the cranial contents
(Wassermann and Zimmermann, 2012), e.g., cerebrospinal
fluid and foraminas in cranial bone. Long-term potentiation
(LTP) and long-term depression (LTD) are believed to be key
processes underlying long-term effects of rTMS (Chervyakov
et al., 2015). In vitro experiments of hippocampal slice cultures
suggest that rTMS can alter cortical excitability in terms of
LTP of synaptic transmission inducing an increase in synaptic
strength and postsynaptic AMPA receptor changes (Vlachos
et al., 2012). At the level of functional connectivity, long-
lasting enhancement is reflected by increased hippocampal-
cortical network coupling after rTMS (Wang and Voss,
2015).
How Effective is rTMS in the Treatment of AVH?
As a target region for rTMS in patients with AVH the superior
temporal cortex (STC) is of special interest given converging
multimodal imaging evidence suggesting a crucial role in
AVH generation and perception (Allen et al., 2008; Waters
et al., 2012). The rationale for stimulating this region is to
inhibit cortical overactivity and potentially influence generative
phenomena (i.e., AVH) which are thought to be closely
associated with regionally increased cortical activity. Up to now,
several randomized sham-controlled studies targeting the left
temporoparietal cortex have been conducted and summarized
in seven meta-analyses revealing effect sizes (Hedges’ ‘‘g’’)
ranging from 0.42 (i.e., a close to moderate effect) to 1.04
(regarded as high effect; Aleman et al., 2007; Tranulis et al.,
2008; Freitas et al., 2009; Slotema et al., 2012, 2014). With the
inclusion of the studies with larger patient samples, the mean
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weighted effect size of rTMS directed at the left temporoparietal
area for AVH appears to decrease over time, although the
effect is still significant (Slotema et al., 2012, 2014; Hoffman
et al., 2013). Of note, Slotema and colleagues showed that the
effect of rTMS was no longer significant at one month of
follow-up revealing a mean weighted effect size of 0.40 (95%
confidence interval = −0.23–0.102; Slotema et al., 2012). For
a detailed description of the included studies, please see tables
provided by Slotema and colleagues. Side effects were mild
and the number of dropouts in the real TMS group was not
significantly higher than in the sham group. Only few MRI
studies investigated other regions than the left temporoparietal
area as target regions for rTMS. Abnormal activation of the
right hemisphere regions such as the inferior frontal gyrus
and the postcentral gyrus is a frequently reported finding in
patients who experience persistent AVH (Kuhn and Gallinat,
2012). Activation changes have been most consistently shown
for areas of the prefrontal and temporal cortices (Allen et al.,
2007; Sommer et al., 2008; Raij et al., 2009). Based on former
findings in neuroimaging studies that both the right and the
left temporal activation are associated with AVH (Shergill et al.,
2000; Sommer et al., 2007) three studies directed rTMS at the
right comparing with the left temporoparietal gyrus for the
treatment of AVH (Lee et al., 2005; Jandl et al., 2006; Loo
et al., 2010). According to these studies, no superior effects of
right-sided stimulation (Slotema et al., 2014) were observed.
Correspondingly, neither stimulation of Brocas´ area nor its
contralateral homologue was an effective target (Schonfeldt-
Lecuona et al., 2004). Overall, these findings support the notion
that deficient generation, monitoring and perception of inner
speech rather than speech expression are disrupted functions
in patients with persistent AVH (Shergill et al., 2000; Wolf
et al., 2011). Abnormal STC function clearly plays a critical
role in the expression of AVH, especially in those patients
presenting with chronic and treatment-refractory symptoms.
Recent studies showed that stimulation of this region with
low-frequency rTMS may reduce the severity and frequency
of AVH in schizophrenia patients, but the duration of the
effect of rTMS may be less than one month (Slotema et al.,
2012).
Methodological Issues with TMS and the
Challenge of Treating Phenotypic Diversity
As briefly discussed in the previous paragraph, it is noteworthy
that therapeutic effects of rTMS in AVH patients are not
long-lasting, and that along with publication of studies with
larger patient populations, the effect size of rTMS over the left
temporoparietal area has decreased over time (Slotema et al.,
2012, 2014). Several studies published between 2004 and 2014
did not observe beneficial effects of rTMS in the treatment of
persistent AVH (Schonfeldt-Lecuona et al., 2004; Slotema et al.,
2011; Blumberger et al., 2012; Rosenberg et al., 2012; Bais et al.,
2014). Several reasons may account for these phenomena. Two
specific aspects of stimulation will be discussed, which may be
superior to left sided STC intervention and which may also
account for these variable results. Subsequently we will address
the problem of the phenotypic diversity which is inherent to
AVH both at the neural and phenomenological level.
Is Bilateral Stimulation Superior?
It may be conceivable that bilateral could be superior over
unilateral stimulation, especially given known dissociations of
left- vs. right-hemispheric function. Up to now, however, only
one study examined bilateral rTMS of the TPJ (Bais et al., 2014).
The authors suggested that AVH frequency might be one of
the most sufficient parameters to measure the responsiveness
of left sided rTMS. In comparison, right-sided rTMS allows for
a more complete management of AVH in terms of emotional
and non-linguistic aspects which are suggested to originate in
the right hemisphere. Contrary to their prediction, however,
Bais and could not show any beneficial effect of bilateral rTMS
in comparison to left sided rTMS and sham in improving
AVH (Bais et al., 2014). Neurophysiological aspects such as
transcallosal inhibition, and fewer rTMS impulses (50%) in a
bilateral design (Thiel et al., 2006; Bais et al., 2014) might account
for these negative results.
Is STC stimulation alone sufficient?
The functional dominance of STC stimulation over other brain
regions has been questioned by accumulating neuroimaging
data acquired in patients with AVH. For instance, an
association between AVH-severity and STC gray matter
volume loss has been suggested by univariate voxel-based
morphometry studies (Modinos et al., 2013). In contrast,
using a multivariate statistical approach for structural data
analysis, two distinct abnormal structural networks were
recently identified in patients with persistent AVH, including
a bilateral prefrontal system and a bilateral temporal/medial
frontal network (Kubera et al., 2014). The latter structural
network also differed between patients with persistent AVH
compared to non-hallucinating patients (Kubera et al., 2014).
It is possible that unilateral temporoparietal stimulation might
not be sufficient to induce a relevant neuronal change
in both networks, whose mutual interplay has still to be
determined. Also, the relationship between structure and
function still remains unresolved, e.g., in individuals with
persistent AVH the impact of neural loss to neural network
transmission, including effects in more remote neural networks,
is unclear.
From a functional point of view, both ‘‘symptom capture’’
(i.e., inferring AVH-related brain activity from symptom
occurrence) and ‘‘symptom interference’’ (i.e., inferring AVH-
related brain dysfunction from paradigm-driven data) MRI
studies have been conducted to investigate neural activation
patterns in schizophrenia patients experiencing treatment-
resistant AVH (Lawrie et al., 2002; Mechelli et al., 2007;
Wolf et al., 2011). The vast majority of these studies focused
on brain activity in speech-related pathways (Lavigne et al.,
2015), according to the prevailing model of AVH suggesting
a link between symptom generation and dysfunctional inner
speech perception and monitoring (Hugdahl et al., 2008).
From these studies, the left STC emerged as regions linked to
AVH and in turn set the rationale for targeted stimulation.
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Yet the left temporal cortex, although a crucial neural node
for hallucinatory symptom expression, is not the sole region
which is thought to be involved in AVH generation and
persistence. The prefrontal cortices have been frequently found
to exhibit abnormal neural activity in patients with AVH, both
at the level of regional function and at the level of functional
connectivity (Kuhn and Gallinat, 2012; Alderson-Day et al.,
2015). Although the processes subserved by abnormal prefrontal
activity in patients experiencing AVH are not fully elucidated
at present, several explanations have been put forward, such
as deficient attentional and executive control over speech- and
self-monitoring relevant brain regions. In addition, converging
evidence suggests that AVH are not related to regional brain
dysfunction alone, but rather to abnormal neural network
coupling in several distinct neural networks including systems
engaged in language, attention, executive function, memory and
self-referential processing (Stephane et al., 2001; Allen et al.,
2008; Wolf et al., 2011; Diederen et al., 2013). Thus, single-
site stimulation may not fully cover all key regions involved
in AVH pathophysiology. In this regard, bilateral or bifocal
stimulation could be a promising approach. Based on the
hypothesis of temporal hyperactivity and frontal hypoactivation
in schizophrenia patients presenting with AVH, Brunelin and
colleagues used a different non-invasive stimulation method,
i.e., tDCS (Brunelin et al., 2012). Unlike TMS, in tDCS a weak
direct current passes through the brain between two electrodes,
i.e., modulation of two spatially remote regions is possible.
Brunelin and co-workers used cathodal left temporoparietal
junction (TPJ) stimulation and anodal left dorsolateral prefrontal
stimulation. After five days of treatment a significant decrease
of hallucinatory symptoms was shown, and this effect remained
significant three months after stimulation. These findings
were recently replicated (Mondino et al., 2015) and provides
a promising outlook for further clinical trials. Nevertheless,
given that tDCS is a relatively new technique employed in
AVH treatment, several stimulation parameters (e.g., electrode
placement and stimulation intensity, frequency and duration)
have to be investigated in more detail to optimize future
treatment options (Koops et al., 2015).
It is noteworthy that although the lateral prefrontal and
temporal cortices clearly are involved in AVH generation, there
is also good evidence suggesting a role of cortical midline
regions in AVH symptom expression. Abnormal cerebral blood
flow could also be detected not only in the primary temporal
cortex and Broca’s area, but also in the cingulate cortex (Wolf
et al., 2012; Kindler et al., 2013). In a recent study exploring
resting-state functional connectivity of the brain, cross-network
abnormalities could be detected between the so called ‘‘default
mode network’’ (DMN) and the ‘‘salience network,’’ including
core midline regions such as the bilateral paracingulate cortex
and bilateral anterior cingulate cortex (Alonso-Solís et al., 2015).
Of note, DMN subsystems have been essentially involved in
self-referential and mnemonic processes (Andrews-Hanna et al.,
2010; Sambataro et al., 2013). Abnormal network interactions
between the DMN and language-processing and auditory
networks could well explain deficient self-monitoring and a
lack of self-referential attribution of voices (Northoff and Qin,
2011). This body of evidence indicates important contributions
of cortical midline regions to the pathomechanisms of persistent
AVH. TMS alone might be insufficient to stimulate these regions
in treatment-resistant patients.
The Challenge of Phenotypic Diversity
When treating AVH in patients with schizophrenia using focal
stimulation techniques, the clinical endpoint appears to be clearly
defined. In the vast majority of cases, this is at least a reduction
in overall AVH severity. Yet it should be kept in mind that
schizophrenia is a phenomenologically heterogeneous disorder
with several distinct phenotypic presentations at both the clinical
and neurobiological level, and the very same heterogeneity
also applies to persons with chronic AVH. In addition, the
multidimensionality of AVH has been long acknowledged by
phenomenological research (Kronmüller et al., 2011; McCarthy-
Jones et al., 2014), but research has only recently begun to
specifically explore therapeutic effects on distinct symptom
domains (Leff et al., 2013).
Apart from refining and technically developing stimulation
techniques per se, a major focus of future research will be
the identification of markers which can predict stimulation
treatment response. An approach which might prove to
be helpful for predicting responders and non-responders in
the future is subtyping AVH patients according to both
neurobiological and clinical criteria. For instance, it has been
attempted, albeit with limited success, to improve responsiveness
to rTMS by targeting the site of maximal neural activation
associated with the hallucinatory event (Slotema et al., 2011).
More recently, Homan and colleagues (Homan et al., 2012)
showed that higher resting-brain perfusion as measured with
arterial spin labeling in the left STC prior to treatment predicted
a clinical response to rTMS (Homan et al., 2012). This marker
may guide stratification strategies in future interventional trials.
Also, it is important to acknowledge that certain symptom
characteristics, such as location of voices in inner our outer
space, may map to distinct neural correlates. In this respect, a
relationship between white matter volume in the right temporal
junction and spatial features such as outer vs. inner location
of voices has been identified (Plaze et al., 2011). However,
stimulation of the right temporal lobe could not show a superior
treatment effect. A possible explanation is that there may well
be structural differences between hallucinating characterized by
‘‘physical’’ features with yet unknown consequences for brain
function and treatment response. Another explanation for non-
response to stimulation could include neural ceiling effects, e.g.,
related to various degrees of subjective symptom control. Over
time, patients with persistent AVH seek for ways of coping
with their voices, e.g., by deliberately directing their attentional
focus to specific external stimuli (which can be auditory) or
by employing individual modes of verbal control. The degree
of control over AVH is associated with distinct frontotemporal
cortical correlates in contrast to physical or affective symptom
dimensions (Wolf et al., 2012). Also, increased frontotemporal
connectivity in hallucinating patients is modulated by the degree
of control over verbal material (Lavigne et al., 2015). Thus, it
is possible that different degrees of control over AVH severity
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prior to therapeutic stimulation could influence treatment
response.
McCarthy-Jones and colleagues proposed different subtypes
of AVH, which might respond to different treatment modalities.
These subtypes may be identified at the levels phenomenology,
cognition, neurology, etiology, treatment response, diagnosis,
and voice hearer’s own interpretation (McCarthy-Jones et al.,
2014). Particularly, an AVH subtype characterized at a neural
level by chronic deafferentiation of the auditory cortex is
proposed, according to the hypothesis of AVH as misattributed
forms of inner speech (Ford and Mathalon, 2005). This subtype
might be specifically responsive to focal stimulation treatment,
i.e., rTMS or tDCS. Furthermore, specific subtypes might
show both common and distinct regions of activation in both
‘‘symptom capture’’ and ‘‘symptom interference’’ studies, so
that future neuroimaging studies may consider specific subtypes
in their protocol and report details of AVH phenomenology.
The majority of functional neuroimaging studies used total
severity and frequency scores of hallucinations (Auditory
Hallucinations Rating Scale (AHRS), Auditory Hallucinations
Subscale/Psychotic Symptom Rating Scale [AHS/PSYRATS]) as
main outcome parameters. To discriminate more fine-grained
aspects of change in hallucinations, especially in homogenous
subgroups, it might be advantageous to describe different
phenomenological dimensions before and their changes after
focal therapy. The PSYRATS and a 4-dimensional model within
the AHS has previous been recommended to integrate into
research and clinical applications (Woodward et al., 2014).
Conclusion
In the past decade non-invasive brain stimulation techniques
became increasingly relevant for the treatment of drug-refractory
AVH. Evidence for ECT for specifically treating AVH is very
limited. There is evidence for beneficial effects of rTMS over
left temporal and temporoparietal areas, but effect sizes for
this treatment modality are moderate, and beneficial long-
term effects are unlikely. It has been suggested that rTMS
may reduce aberrant internally generated activity associated
with AVH at the site of stimulation. Still, the role of rTMS
in changing aberrant network function putatively involved
in the generation of AVH has to be clarified. A further
major challenge for future research is identifying of patients
who do respond to treatment and those who do not or
only insufficient. Supported by neuroimaging evidence, the
magnitude of left STC activity has been promoted as a potential
predictor of clinical improvement. Given the phenomenological
diversity of schizophrenia and AVH in particular, it is
expected that subtyping patients with AVH will essentially
contribute to identify responders from non-responders for focal
augmentative therapies. In this respect, in accordance with
other authors we strongly advocate further development of
reliable and valid psychometric assessments and neurobiological
markers paralleling the optimization of future stimulation
protocols. Other neuromodulatory interventions, such as tDCS
provide very promising data as well but larger trials are
needed.
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